Literature DB >> 8497045

Human papillomavirus type 18 E7 protein requires intact Cys-X-X-Cys motifs for zinc binding, dimerization, and transformation but not for Rb binding.

M C McIntyre1, M G Frattini, S R Grossman, L A Laimins.   

Abstract

Human papillomavirus type 18 (HPV-18) E7 proteins bind zinc through Cys-X-X-Cys repeats located at the C terminus of the protein. In order to examine the role of these cysteine motifs in E7 function, we expressed the HPV-18 E7 protein in bacteria and found that purified E7 forms a dimer through interactions with zinc. Mutants with single mutations within the Cys-X-X-Cys motifs bound a reduced level of zinc in a zinc blot assay, while a double mutant lost all zinc-binding activity. When expressed in vivo, none of the mutants cooperated with an activated ras oncogene to transform primary rat embryo fibroblasts, but all mutants retained nearly wild-type Rb-binding activity. The results indicate that the cysteine motifs play an important role in transformation by HPV-18 E7 but do not contribute to Rb binding.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8497045      PMCID: PMC237652          DOI: 10.1128/JVI.67.6.3142-3150.1993

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Potential metal-binding domains in nucleic acid binding proteins.

Authors:  J M Berg
Journal:  Science       Date:  1986-04-25       Impact factor: 47.728

2.  Identification of T4D bacteriophage gene product 12 as the baseplate zinc metalloprotein.

Authors:  J Zorzopulos; L M Kozloff
Journal:  J Biol Chem       Date:  1978-08-10       Impact factor: 5.157

3.  The major human papillomavirus protein in cervical cancers is a cytoplasmic phosphoprotein.

Authors:  D Smotkin; F O Wettstein
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

4.  Human papillomavirus in clinically and histologically normal tissue of patients with genital cancer.

Authors:  J C Macnab; S A Walkinshaw; J W Cordiner; J B Clements
Journal:  N Engl J Med       Date:  1986-10-23       Impact factor: 91.245

5.  Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines.

Authors:  C C Baker; W C Phelps; V Lindgren; M J Braun; M A Gonda; P M Howley
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

6.  Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein.

Authors:  D Smotkin; F O Wettstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

7.  Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA.

Authors:  L Pirisi; S Yasumoto; M Feller; J Doniger; J A DiPaolo
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

8.  Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells.

Authors:  G Matlashewski; J Schneider; L Banks; N Jones; A Murray; L Crawford
Journal:  EMBO J       Date:  1987-06       Impact factor: 11.598

9.  Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes.

Authors:  A Schneider-Gädicke; E Schwarz
Journal:  EMBO J       Date:  1986-09       Impact factor: 11.598

10.  Construction of a new family of high efficiency bacterial expression vectors: identification of cDNA clones coding for human liver proteins.

Authors:  K K Stanley; J P Luzio
Journal:  EMBO J       Date:  1984-06       Impact factor: 11.598

View more
  42 in total

1.  Destabilization of the retinoblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes.

Authors:  A M Helt; D A Galloway
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Mechanisms of human papillomavirus-induced oncogenesis.

Authors:  Karl Münger; Amy Baldwin; Kirsten M Edwards; Hiroyuki Hayakawa; Christine L Nguyen; Michael Owens; Miranda Grace; Kyungwon Huh
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

Review 3.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

4.  USP11 stabilizes HPV-16E7 and further modulates the E7 biological activity.

Authors:  Ching-Hui Lin; Hung-Shu Chang; Winston C Y Yu
Journal:  J Biol Chem       Date:  2008-04-11       Impact factor: 5.157

5.  Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1.

Authors:  Y E Chang; A P Poon; B Roizman
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

6.  Human adenovirus early region 4 open reading frame 1 genes encode growth-transforming proteins that may be distantly related to dUTP pyrophosphatase enzymes.

Authors:  R S Weiss; S S Lee; B V Prasad; R T Javier
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

7.  Anchorage-independent transcription of the cyclin A gene induced by the E7 oncoprotein of human papillomavirus type 16.

Authors:  A Schulze; B Mannhardt; K Zerfass-Thome; W Zwerschke; P Jansen-Dürr
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

8.  Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity.

Authors:  M N Ruesch; L A Laimins
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

9.  Positive and negative regulation of cell proliferation by E2F-1: influence of protein level and human papillomavirus oncoproteins.

Authors:  R M Melillo; K Helin; D R Lowy; J T Schiller
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

10.  The human cytomegalovirus UL94 open reading frame encodes a conserved herpesvirus capsid/tegument-associated virion protein that is expressed with true late kinetics.

Authors:  B A Wing; G C Lee; E S Huang
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.